It's a finding that has been called "comforting," "reassuring," and "good news," here at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting. The warm words are for the long-term results of a study of women who became pregnant after an early stage breast cancer diagnosis.

Lead study author Matteo Lambertini, MD, a medical oncologist at the Institut Jules Bordet in Brussels, Belgium, reported that, after a median follow-up of about 12 years from cancer diagnosis among 1200 women, there was no difference in disease-free survival between women who became pregnant and those who did not (hazard ratio [HR], 0.85; P = .15).

In other words, a pregnancy did not raise the risk of breast cancer recurrence or death. Importantly, the finding also applied to women with estrogen-receptor (ER)-positive disease (HR, 0.94; P = .68), the primary study outcome.  Pregnancy after breast cancer is "safe" and "should not be discouraged," summarized Dr Lambertini during a press conference.

A startling 82 percent of postmenopausal women did not identify such bone fractures as a possible risk factor for osteoporosis, according to results from a new Harris Poll survey conducted on behalf of Radius Health, in partnership with HealthyWomen and the National Osteoporosis Foundation.

Physical activity appears to clear away brain fog and significantly improve cognitive function in breast cancer survivors experiencing poor working memory and executive function following chemotherapy, according to researchers.

In a national study of 299 women with a mean duration of 8 years since chemotherapy for breast cancer, objective measures showed that moderate-to-vigorous physical activity (MVPA) was directly associated with significantly fewer cancer-related symptoms, such as fatigue (P < .001), say Diane K. Ehlers, from the Department of Kinesiology and Community Health, University of Illinois at Urbana-Champaign, and colleagues.

Historical and current data support the role of imaging-based axillary lymph node staging and sentinel lymph node biopsy (SLNB) as the standard of care for axillary management in women with a diagnosis of breast cancer, before and after neoadjuvant systemic therapy (NST).